Buy CPRX now: trend is bullish (stacked moving averages) and fundamentals are accelerating (Q3’25 revenue/EPS up mid-to-high teens/20%).
Near-term setup is slightly extended (RSI 65.7 and price sitting just below R1 ~25.26), but for an impatient buyer the risk/reward is still favorable given strong earnings momentum and supportive Street targets ($33).
No Intellectia edge today (no AI Stock Picker or SwingMax signal), so this is a trend/fundamentals-driven buy rather than a “signal” buy.
Technical Analysis
Trend: Bullish structure with SMA_5 > SMA_20 > SMA_200, indicating a sustained uptrend.
Momentum: MACD histogram +0.16 (above zero) but positively contracting, suggesting upside momentum is still positive but cooling.
RSI: RSI_6 = 65.7 (upper-neutral), consistent with strength but not a fresh oversold entry.
Levels: Pivot 24.51; immediate resistance R1 25.26 (current ~25.07 just below), then R2 25.72. Supports at S1 23.76 and S2 23.30.
Pattern-based projection: Similar-pattern stats imply a constructive bias (next week +3.92%, next month +11.88% probability-weighted).
Options Data
Bullish
Open Interest Put-Call Ratio
Neutral
Option Volume Put-Call Ratio
Positioning: Open interest put/call ~0.92 = slightly call-leaning but broadly balanced (not crowded).
Flow today: Put/call volume ratio = 1.0 (neutral intraday sentiment), with volume elevated vs 30D average (today vs avg ~15.18x), signaling attention despite small absolute contracts.
Volatility: IV 30D ~51.1 vs historical vol ~34.5 = options priced rich; sentiment is not fearful, but option premiums are elevated.
IV percentile ~54.8 / IV rank ~14.5: current IV is mid-pack vs the past year, not extreme.
Technical Summary
Sell
2
Buy
7
Positive Catalysts
Strong Q3’25 beat backdrop cited by analysts; recent results and outlook commentary support continued rerating.
Analyst targets raised to $33 (Oppenheimer, Citi) with Outperform/Buy ratings—reinforces bullish institutional narrative.
Clean sentiment tape: no negative news in the past week, reducing headline risk near-term.
Pattern-based forward bias suggests continued upside tailwind over 1W–1M horizon.
Neutral/Negative Catalysts
with RSI elevated; short-term upside may be choppy if it fails to clear that level.
Recent trend: price targets moved up and bullish ratings reiterated following Q3’25 strength.
2025-11-07 Oppenheimer: PT raised to $33 from $32, reiterates Outperform; highlighted Q3 revenue $148.4M beating expectations and strong non-GAAP net income.
2025-11-07 Citi: PT raised to $33 from $31, reiterates Buy; sees upper end of 2025 outlook as achievable.
Wall Street pros: earnings momentum, margin strength, and credible path to higher-end guidance.
Wall Street cons: fewer near-term “new” catalysts flagged in the dataset (no fresh news/events), so the next leg up likely depends on continued execution/next updates.
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34 USD with a low forecast of 33 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34 USD with a low forecast of 33 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.910
Low
33
Averages
34
High
35
Current: 23.910
Low
33
Averages
34
High
35
Oppenheimer
Leland Gershell
Outperform
maintain
$32 -> $33
AI Analysis
2025-11-07
Reason
Oppenheimer
Leland Gershell
Price Target
$32 -> $33
AI Analysis
2025-11-07
maintain
Outperform
Reason
Oppenheimer analyst Leland Gershell raised the firm's price target on Catalyst Pharmaceuticals to $33 from $32 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 total revenue of $148.4M, coming in well above its/consensus estimates of $136M/$137M and driving non-GAAP net income of $86.1M.
Citi
Buy
maintain
$31 -> $33
2025-11-07
Reason
Citi
Price Target
$31 -> $33
2025-11-07
maintain
Buy
Reason
Citi raised the firm's price target on Catalyst Pharmaceuticals to $33 from $31 and keeps a Buy rating on the shares. The firm sees the upper end of the company's 2025 outlook as potentially achievable following the Q3 report.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CPRX
